Endpoints
toxicities
ADVERSE EVENTS, MYELOMA
Safety endpoints included incidence, nature, and severity of adverse events (AEs) and serious AEs (SAEs), and occurrence of dose-limiting toxicities. Efficacy endpoints included overall response rate (ORR), duration of response (DOR), progression-free survival (PFS) and OS. Response was assessed by investigators using International Myeloma Working Group 2016 criteria (